Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis

References

• Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636. doi: 10.1016/S0140-6736(18)30481-1
   PubMed Web of Science ®Google Scholar
• Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78–88. doi: 10.1016/S1474-4422(22)00289-7
   PubMed Web of Science ®Google Scholar
• Vollmer TL, Nair KV, Williams IM, et al. Multiple sclerosis phenotypes as a continuum: the role of neurologic reserve. Neurol Clin Pract. 2021;11(4):342–351. doi: 10.1212/CPJ.0000000000001045
   PubMedGoogle Scholar
• Cree BAC, Oksenberg JR, Hauser SL. Multiple sclerosis: two decades of progress. Lancet Neurol. 2022;21(3):211–214. doi: 10.1016/S1474-4422(22)00040-0
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Kolb C, Ramanathan M, et al. Interferon β for multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(11):a032003. doi: 10.1101/cshperspect.a032003
   PubMed Web of Science ®Google Scholar
• Comi G, Bar-Or A, Lassmann H, et al. Role of B cells in multiple sclerosis and related disorders. Ann Neurol. 2021;89(1):13–23. doi: 10.1002/ana.25927
   PubMed Web of Science ®Google Scholar
• Cencioni MT, Mattoscio M, Magliozzi R, et al. B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies. Nat Rev Neurol. 2021;17(7):399–414. doi: 10.1038/s41582-021-00498-5
   PubMed Web of Science ®Google Scholar
• Lee A. Ublituximab: first approval. Drugs. 2023;83:455–459. doi: 10.1007/s40265-023-01854-z
   PubMedGoogle Scholar
• Dalle S, Reslan L, Besseyre de Horts T, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther. 2011;10(1):178–185. doi: 10.1158/1535-7163.MCT-10-0385
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the Therapeutic response to rituximab. JAMA Neurol. 2015;72(9):989–995. doi: 10.1001/jamaneurol.2015.1276
   PubMed Web of Science ®Google Scholar
• Mahaweni NM, Olieslagers TI, Rivas IO, et al. A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism. Sci Rep. 2018;8(1):15983. doi: 10.1038/s41598-018-34258-1
   PubMedGoogle Scholar
• Huang D, Alvarez E, Miskin H, et al. Ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody (mAb), demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) relative to other anti-CD20 mAbs (P7-3.011). Neurology. 2023;100:3185
   Web of Science ®Google Scholar
• Ferrara C, Grau S, Jäger C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011;108:12669–12674. doi: 10.1073/pnas.1108455108
   PubMed Web of Science ®Google Scholar
• Lovett-Racke AE, Gormley M, Liu Y, et al. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol. 2019;332:187–197. doi: 10.1016/j.jneuroim.2019.04.017
   PubMed Web of Science ®Google Scholar
• Fox E, Lovett-Racke AE, Gormley M, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420–429. doi: 10.1177/1352458520918375
   PubMed Web of Science ®Google Scholar
• Fox E, Wray S, Shubin R, et al. Long-term follow-up results from the phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 mAb, in patients with RMS (1167). Neurology. 2020;94:1167. doi: 10.1177/1352458520918375
   Web of Science ®Google Scholar
• Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704–714. doi: 10.1056/NEJMoa2201904
   PubMed Web of Science ®Google Scholar
• Alvarez E, Steinman L, Hartung H-P, et al. Disease outcomes with ublituximab in participants with highly active disease: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis (P6-3.002). Neurology. 2023;100:3092
   Web of Science ®Google Scholar
• Hartung H, Steinman L, Fox E, et al. Ublituximab efficacy outcomes in relapsing multiple sclerosis patient subgroups in the ULTIMATE I and II studies. Academy of Neurology. (EAN); NJ USA: Wiley; 2022. p. 631–631.
   Google Scholar
• Zhang Y, Gonzalez Caldito N, Shirani A, et al. Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Ther Adv Neurol Disord. 2020;13:1756286420969016. doi: 10.1177/1756286420969016
   Web of Science ®Google Scholar
• Steinman L, Fox E, Hartung H-P, et al. Ublituximab efficacy in treatment-naive participants with relapsing multiple sclerosis in the phase 3 ULTIMATE I and II studies (P6-3.015). Neurology. 2023;100:3199
   Web of Science ®Google Scholar
• Rendas-Baum R, Yang M, Cattelin F, et al. A novel approach to estimate the minimally important difference for the fatigue impact scale in multiple sclerosis patients. Qual Life Res. 2010;19(9):1349–1358. doi: 10.1007/s11136-010-9704-7
   PubMed Web of Science ®Google Scholar
• Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36(1):3–10. doi: 10.1016/j.ymeth.2005.01.001
   PubMed Web of Science ®Google Scholar
• Alvarez E, Steinman L, Fox E, et al. Neutralizing antibodies and antidrug antibodies in the ublituximab phase 3 ULTIMATE I and II studies in relapsing multiple sclerosis. Mult Scler J. 2022;28:67
   Web of Science ®Google Scholar
• Dunn N, Juto A, Ryner M, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler J. 2018;24(9):1224–1233. doi: 10.1177/1352458517720044
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546–557. doi: 10.1056/NEJMoa1917246
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2016;376:221–234. doi: 10.1056/NEJMoa1601277
   PubMed Web of Science ®Google Scholar
• Sawas A, Farber CM, Schreeder MT, et al. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. Br J Haematol. 2017;177(2):243–253. doi: 10.1111/bjh.14534
   PubMed Web of Science ®Google Scholar
• Sharman JP, Farber CM, Mahadevan D, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. Br J Haematol. 2017;176(3):412–420. doi: 10.1111/bjh.14447
   PubMed Web of Science ®Google Scholar
• Lunning M, Vose J, Nastoupil L, et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019;134(21):1811–1820. doi: 10.1182/blood.2019002118
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Lunning MA, Vose JM, et al. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019;6(2):e100–e109. doi: 10.1016/S2352-3026(18)30216-3
   PubMed Web of Science ®Google Scholar
• Sharman JP, Brander DM, Mato AR, et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 2021;8(4):e254–e266. doi: 10.1016/S2352-3026(20)30433-6
   PubMed Web of Science ®Google Scholar
• Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (Baltimore). 2019;98(25):e15944. doi: 10.1097/MD.0000000000015944
   PubMed Web of Science ®Google Scholar
• Garff-Tavernier ML, Herbi L, de Romeuf C, et al. Ublituximab, an optimized anti-CD20 monoclonal antibody, demonstrates greater NK-Mediated ADCC than rituximab in Waldenstrom’s macroglobulinemia patients supporting a therapeutic strategy with ublituximab. Blood. 2012;120:1654–1654. doi: 10.1182/blood.V120.21.1654.1654
   Web of Science ®Google Scholar
• Hartung HP. Ocrelizumab shorter infusion: primary results from the ENSEMBLE PLUS substudy in patients with MS. Neurol(r) Neuroimmunol Neuroinflammation. 2020;7(5):7. doi: 10.1212/NXI.0000000000000807
   Web of Science ®Google Scholar
• Jakimovski D, Vaughn CB, Eckert S, et al. Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opin Drug Saf. 2020;19(9):1121–1142. doi: 10.1080/14740338.2020.1805430
   PubMed Web of Science ®Google Scholar
• ICER. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value [online]. Accessed 2023 Dec 6
   Google Scholar
• Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–1273. doi: 10.1016/S0140-6736(18)30475-6
   PubMed Web of Science ®Google Scholar
• Roos I, Hughes S, McDonnell G, et al. Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis. JAMA Neurol. 2023;80(8):789–797. doi: 10.1001/jamaneurol.2023.1625
   PubMed Web of Science ®Google Scholar
• Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132–1140. doi: 10.1001/jamaneurol.2020.1568
   PubMed Web of Science ®Google Scholar
• Montalban X, Cohen JA, Comi G, et al. Ofatumumab reduces disability progression Independent of relapse activity in patients with relapsing multiple sclerosis (1845). Neurology. 2020;94:1845. doi: 10.1212/WNL.0000000000009371
   Web of Science ®Google Scholar
• Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol. 2021;78(5):558–567. doi: 10.1001/jamaneurol.2021.0405
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Dwyer MG, Carl E, et al. Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. Ther Adv Neurol Disord. 2020;13:1756286420970754. doi: 10.1177/1756286420970754
   Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–1303. doi: 10.1056/NEJMoa1014656
   PubMed Web of Science ®Google Scholar
• Chisari CG, Sgarlata E, Arena S, et al. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022;269(1):159–183. doi: 10.1007/s00415-020-10362-z
   PubMed Web of Science ®Google Scholar
• Iacobaeus E, Burkill S, Bahmanyar S, et al. The national incidence of PML in Sweden, 1988-2013. Neurology. 2018;90:e498–e506. doi: 10.1212/WNL.0000000000004926
   PubMed Web of Science ®Google Scholar
• Bennett CL, Focosi D, Socal MP, et al. Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on adverse reactions. Lancet Haematol. 2021;8(8):e593–e604. doi: 10.1016/S2352-3026(21)00167-8
   PubMed Web of Science ®Google Scholar
• Eis PS, Bruno CD, Richmond TA, et al. Germline genetic risk variants for progressive multifocal leukoencephalopathy. Front Neurol. 2020;11:11. doi: 10.3389/fneur.2020.00186
   PubMed Web of Science ®Google Scholar